Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.836
+0.007 (0.87%)
At close: Dec 5, 2025, 4:00 PM EST
0.810
-0.026 (-3.06%)
After-hours: Dec 5, 2025, 7:39 PM EST
Biofrontera Revenue
Biofrontera had revenue of $6.99M in the quarter ending September 30, 2025, a decrease of -22.46%. This brings the company's revenue in the last twelve months to $37.16M, up 5.11% year-over-year. In the year 2024, Biofrontera had annual revenue of $37.32M with 9.54% growth.
Revenue (ttm)
$37.16M
Revenue Growth
+5.11%
P/S Ratio
0.21
Revenue / Employee
$399,613
Employees
93
Market Cap
9.73M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BFRI News
- 2 days ago - Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities - GlobeNewsWire
- 4 days ago - Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT - GlobeNewsWire
- 22 days ago - Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 4 weeks ago - Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M - GlobeNewsWire
- 4 weeks ago - Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025 - GlobeNewsWire
- 6 weeks ago - Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG - GlobeNewsWire
- 2 months ago - Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - GlobeNewsWire